PRO-SCIENCE
These sources consist of legitimate science or are evidence-based through credible scientific sourcing. Legitimate science follows the scientific method, is unbiased, and does not use emotional words. These sources also respect the consensus of experts in the given scientific field and strive to publish peer-reviewed science. Some sources in this category may have a slight political bias but adhere to scientific principles. See all Pro-Science sources.
- Overall, we rate Cancer Cell Journal as a Pro-Science journal. We also rate them High for factual reporting due to a clean fact check record.
Detailed Report
Bias Rating: PRO-SCIENCE
Factual Reporting: HIGH
Country: USA
Press Freedom Rank: MOSTLY FREE
Media Type: Journal
Traffic/Popularity: Minimal Traffic
MBFC Credibility Rating: HIGH CREDIBILITY
History
Cancer Cell Journal is a peer-reviewed open-access journal published by Cell Press that covers cancer research. According to its about page, “Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. “
Cell Press, based in Cambridge, Massachusetts, publishes over 50 scientific journals. Cell Press Journals are 50% open-access as of 2022.
Read our profile on the United States media and government.
Funded by / Ownership
The Cancer Cell Journal is published by Cell Press which is a subsidiary of Elsevier, a Dutch information and analytics company and one of the world’s foremost providers of scientific, technical, and medical information. It was established in 1880 as a publishing company. Elsevier’s parent company is RELX plc, a British multinational information and analytics company headquartered in London, England. The journal generates revenue through subscription fees and fees for open-access publishing.
Analysis / Bias
Cancer Cell Journal is a hybrid (some open-access) journal that publishes information and research related to cancer research. The journal primarily publishes research such as this CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Cell Press is an open-access/hybrid publisher of scientific journals. There are two types of Open Access Journals, legitimate and predatory, both of which charge the author for publication. Predatory journals often lack peer review and are generally considered not credible. The Cancer Cell Journal is considered a legitimate, open-access publisher that is frequently indexed in PubMed. However, Cell Press has been criticized for retracting some studies.
Although Cell Press has retracted some studies in other publications, Cancer Cell Journal publishes credible scientific studies that are factual and appropriately peer-reviewed.
Failed Fact Checks
- None in the Last 5 years
Overall, we rate Cancer Cell Journal as a Pro-Science journal. We also rate them High for factual reporting due to a clean fact check record. (D. Van Zandt 02/16/2023)
Source: https://www.cell.com/cancer-cell/
Last Updated on February 16, 2023 by Media Bias Fact Check
Left vs. Right Bias: How we rate the bias of media sources
